Figure 3 | Bone Marrow Transplantation

Figure 3

From: Salvage bortezomib–dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial

Figure 3

Kaplan–Meier Plot of PFS II after salvage autologous stem cell transplantation (ASCT) compared with PFS I after initial ASCT (a) and TNT II after salvage ASCT compared with TNT I after initial ASCT (b). The Y axis indicates the event-free survival (event=death or PD (PFS) (a) or next treatment (TNT) (b)).

Back to article page